Confidence in Concept 2012 - Imperial
Lead Research Organisation:
Imperial College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- Imperial College London (Lead Research Organisation)
- Dexcom (Collaboration)
- University College London (Collaboration)
- University of Manchester (Collaboration)
- Edinburgh Bioquarter (Collaboration)
- University of Surrey (Collaboration)
- Cyprotex (Collaboration)
- University of Alabama at Birmingham (Collaboration)
- Biofocus (Collaboration)
- Merieux Institute (Collaboration)
- Baylor College of Medicine (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Cellnovo (Collaboration)
- Dundee Model Railway Club (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Bio Products Laboratory Ltd (Collaboration)
- Pfizer Ltd (Collaboration)
- University of California, San Diego (UCSD) (Collaboration)
- Domainex (Collaboration)
- Peakdale Molecular (Collaboration)
- Research Complex at Harwell (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
People |
ORCID iD |
Publications
Abellona U
(2018)
Towards elucidating a universal panel of diagnostic biomarkers for early hepatocellular carcinoma
in Journal of Hepatology
Al-Kofahi M
(2015)
IL-1ß reduces tonic contraction of mesenteric lymphatic muscle cells, with the involvement of cycloxygenase-2 and prostaglandin E2.
in British journal of pharmacology
Archibald SJ
(2015)
Dalton Discussion 15 - Metal ions in medical imaging: optical, radiopharmaceutical and MRI contrast, 8th-10th September 2014, York.
in Dalton transactions (Cambridge, England : 2003)
Becker F
(2016)
A Critical Role for Monocytes/Macrophages During Intestinal Inflammation-associated Lymphangiogenesis.
in Inflammatory bowel diseases
Buss NA
(2015)
Targeting the annexin 1-formyl peptide receptor 2/ALX pathway affords protection against bacterial LPS-induced pathologic changes in the murine adrenal cortex.
in FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Campos-Pires R
(2015)
Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury.
in Critical care medicine
Cheraghchi-Bashi-Astaneh A
(2013)
Abstract PR04: DNA-PK inhibition resensitizes ovarian cancer cells to cisplatin in vivo and is associated with modulation of AKT pathway signaling
in Clinical Cancer Research
Cook NA
(2017)
A pilot evaluation of a computer-based psychometric test battery designed to detect impairment in patients with cirrhosis.
in International journal of general medicine
Cox IJ
(2016)
Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study.
in World journal of gastroenterology
Curry E
(2015)
Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway
in Molecular Cancer Therapeutics
| Description | Oliver ICiC - JDRF Continuous Glucose Monitoring Roundtable |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.jdrf.org.uk/research/type-1-diabetes-research-roadmap |
| Description | Wigneshweraraj - ICiC1 - Berlin |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Contribution to defining the MRC/BBSRC AMR theme 4 call for applications at a workshop in Berlin. |
| Description | Action Against Cancer grant |
| Amount | £78,000 (GBP) |
| Organisation | Action Against Cancer (AAC) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2012 |
| End | 06/2015 |
| Description | Action Medical Research Project Grant |
| Amount | £188,536 (GBP) |
| Organisation | Action Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Asthma UK Innovations Award |
| Amount | £46,540 (GBP) |
| Funding ID | AUK-IG-2014-286 |
| Organisation | Asthma + Lung UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 03/2016 |
| Description | BBSRC NPIF Phd Studentship |
| Amount | £0 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | BHF Clinical Research Training Fellowship |
| Amount | £186,887 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2015 |
| End | 12/2018 |
| Description | Biomedical research unit (BRU) funding |
| Amount | £165,000 (GBP) |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Department | Respiratory Biomedical Research Unit |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 09/2016 |
| Description | Breaking the scarlet fever transmission chain to reduce invasive streptococcal infection. |
| Amount | £188,536 (GBP) |
| Funding ID | 2596 |
| Organisation | Action Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2019 |
| Description | Breast Cancer Campaign project grant |
| Amount | £191,000 (GBP) |
| Funding ID | 2014MayPR234 |
| Organisation | Breast Cancer Campaign (BCC) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 10/2017 |
| Description | Breast Cancer Campaign small pilot grant |
| Amount | £20,000 (GBP) |
| Funding ID | 2013MaySP004 |
| Organisation | Breast Cancer Campaign (BCC) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2013 |
| End | 08/2014 |
| Description | British Lung Foundation Napp travel fellowship |
| Amount | £750 (GBP) |
| Organisation | British Lung Foundation (BLF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | CRUK Programme Grant |
| Amount | £3,000,000 (GBP) |
| Funding ID | C37/A18784 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2020 |
| Description | Confidence in Concept |
| Amount | £700,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2013 |
| End | 09/2015 |
| Description | Confidence in Concept |
| Amount | £944,000 (GBP) |
| Funding ID | MC_PC_17162 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | Confidence in Concept |
| Amount | £840,000 (GBP) |
| Funding ID | MC_PC_16046 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Confidence in Concept 3 |
| Amount | £800,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 09/2016 |
| Description | Confidence in Concept 4 |
| Amount | £900,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 02/2018 |
| Description | Dexcom Industry Funding |
| Amount | £191,757 (GBP) |
| Organisation | Dexcom |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Doverdale Trust Fund |
| Amount | £16,133 (GBP) |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2014 |
| End | 12/2014 |
| Description | EPSRC i-sense IRC Fellowship |
| Amount | £201,028 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | EPSRC i-sense IRC Fellowship |
| Amount | £184,041 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Egyptian Newton Fund |
| Amount | £150,000 (GBP) |
| Organisation | British Council |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| Description | Halley Stewart Fellowship |
| Amount | £5,000 (GBP) |
| Organisation | Sir Halley Stewart Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 10/2015 |
| Description | Horizon 2020 |
| Amount | € 1,218,879 (EUR) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | |
| Description | ICiC 1 - Quinlan - British Heart Foundation Translational Award Scheme "Development of a haemolysis triple filter for use in extracorporeal circuits" |
| Amount | £317,000 (GBP) |
| Funding ID | TG/18/7/34132 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 06/2022 |
| Description | ICiC 1_Schneider_MAP4K4 Apollo |
| Amount | £2,800,000 (GBP) |
| Organisation | Apollo Therapeutics |
| Sector | Private |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 04/2020 |
| Description | Late Stage Seeding Drug Discovery Award |
| Amount | £4,499,155 (GBP) |
| Funding ID | 205256/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 11/2019 |
| Description | MRC Project Grant |
| Amount | £519,555 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Medicor funding |
| Amount | £200,000 (GBP) |
| Organisation | Medicor Foundation |
| Sector | Charity/Non Profit |
| Country | Liechtenstein |
| Start | 12/2013 |
| Description | Merieux Foundation |
| Amount | € 100,000 (EUR) |
| Organisation | Merieux Foundation |
| Sector | Charity/Non Profit |
| Country | France |
| Start | 08/2014 |
| End | 08/2016 |
| Description | Molecular Dissection of England's Scarlet Fever Upsurge 2015-2016 and Impact on Invasive Infections |
| Amount | £415,642 (GBP) |
| Funding ID | MR/P022669/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 06/2020 |
| Description | NIHR Imperial BRC - BioAID |
| Amount | £421,836 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Imperial Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 03/2017 |
| Description | NIHR Invention for Innovation (I4I) |
| Amount | £718,235 (GBP) |
| Funding ID | II-LA-0313-20004 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 04/2017 |
| Description | NIHR Respiratory Biomedical Research Unit funding for PhD fellows |
| Amount | £180,000 (GBP) |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Department | NIHR Biomedical Research Unit |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2013 |
| End | 08/2016 |
| Description | Proof of Concept funding - Imperial Innovations |
| Amount | £24,954 (GBP) |
| Organisation | Imperial Innovations |
| Sector | Private |
| Country | United Kingdom |
| Start | 12/2014 |
| End | 04/2015 |
| Description | Royal Brompton & Harefield NHS Foundation Trust Seed Funding |
| Amount | £10,000 (GBP) |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 10/2016 |
| Description | Royal Society of Chemistry Travel Grant |
| Amount | £3,065 (GBP) |
| Organisation | Royal Society of Chemistry |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Studentship EPSRC CDT in Neurotechnology for Life and Health |
| Amount | £96,000 (GBP) |
| Organisation | Imperial College London |
| Department | EPSRC Centres for Doctoral Training |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2018 |
| Description | Targeting bacterial virulence as a novel antibiotic and vaccine approach |
| Amount | £106,212 (GBP) |
| Funding ID | BB/R505766/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 10/2021 |
| Description | Understanding and exploiting Group A streptococcal anti-chemotactic proteases in vaccines for infection |
| Amount | £1,655,729 (GBP) |
| Funding ID | 215539/Z/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 06/2023 |
| Description | Wellcome Portfolio Grant for Alpha 1 antitypsin deficiency and haemophilia |
| Amount | £6,400,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2017 |
| Description | Wellcome Trust Extension Translation Award - A Bio-inspired Artificial Pancreas for Control of Type 1 Diabetes in the Home |
| Amount | £193,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2016 |
| Description | Wellcome Trust Imperial ISSF Sabbatical Award |
| Amount | £3,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2014 |
| End | 01/2015 |
| Description | Wellcome Trust Seeding Drug Discovery |
| Amount | £2,700,000 (GBP) |
| Funding ID | 10638/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 05/2017 |
| Description | icIC 1 - Herrero- Dexcom |
| Amount | £450,000 (GBP) |
| Organisation | Dexcom |
| Sector | Private |
| Country | United States |
| Start | 11/2018 |
| End | 11/2019 |
| Title | Edwards - P47173 |
| Description | Developed a novel cell based screening assay involving the activation of two virus-inducible transcription factors; NF-?B, required for over 100 pro-inflammatory cytokines and IRF3; a transcription factor central to IFN gene expression. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Provided To Others? | No |
| Impact | N/A |
| Title | Giamas - LMTK3 inhibitors |
| Description | Potential new inhibitor against a kinase implicated in cancer development. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | None stated at present |
| Title | Griesenbach - P47167-plasmids suitable for the production of F/HN pseudotyped lentiviral vectors carrying FVIII |
| Description | As part of this project Professor Griesenbach's team generated plasmids suitable for the production of F/HN pseudotyped lentiviral vectors carrying FVIII. Lentiviral vectors have been constructed and assessed for efficacy in relevant models |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | Presented work related to the novel vector platform at the American Society for Gene Therapy Symposium 2014 |
| Title | Srsikandan - ICiC1 - E-VIG |
| Description | E-IVIG demonstrated to be a highly purified protective derivative of regular IVIG in vitro and in treatment of invasive group A streptococcal infection. Reagent described in Scientific Reports (Reglinski et al, 2015) |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | Other academic groups have used IVIG as a positive control for development of surrogate of immunity assays for GAS . |
| Title | ICiC 1 - Herrero - ABC4D Phase 3 Dataset |
| Description | The database includes data from 25 adults with type 1 diabetes on multiple daily injection, insulin pump therapy and wearing a continuous glucose monitor, and using the ABC4D app. Each participant was using the system for a duration of 6 months. The dataset includes: continuous glucose data and manual data logs (carbohydrates, insulin, exercise, glucose trends, capillary glucose). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | The database is currently being used to develop machine learning algorithms for glucose prediction and classification. |
| Description | Edward, M - P47173 - Domainex |
| Organisation | Domainex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Imperial provided in-house small molecule library |
| Collaborator Contribution | Domainex screened Imperial in-house small molecule library |
| Impact | Azithromycin augments RV-induced type I IFN and type III IFNs via interaction with MAVS. Michael R Edwards Oral Presentation, XVI International Symposium on Respiratory Viral Infections Seoul, Korea 2014. http://www.themacraefoundation.org/wp-content/uploads/2013/08/Final-Program-2.pdf Novel inhibitors of TGF-? activating kinase (TAK1) uncouple beneficial anti-viral innate immunity from harmful virus-induced pro-inflammatory responses in models of rhinovirus infection. Michael R. Edwards, Katie Chapman, Jennifer J. Haas, Louise Slater, Albert Jaxa-Chamiec, Caroline Low, Hayley Cordingley, Roberto Solari, Sebastian L. Johnston Catherine Tralau-Stewart. Poster Presentation, American Thoracic Society, San Diego, USA 2014. The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved. |
| Start Year | 2013 |
| Description | Edwards - P47173 - UCSD |
| Organisation | University of California, San Diego (UCSD) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Edwards team has identified demethylasterrquinone as a novel inhibitor of TAK1 and NF-?B |
| Collaborator Contribution | Mike Pirrung & Nicholas Webster at Uni of California, San Diego - provided library of novel asterrquinones based around the structure of demethylasterrquinone (under MTA) |
| Impact | The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved. |
| Start Year | 2013 |
| Description | Edwards, M - P47173 - Pfizer |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Edwards team identified several new that increased virus-induced IFN induction by 200-250% and decreased pro-inflammatory cytokine induction by 60-80% from the small library of macrolides provided for screening by Pfizer. |
| Collaborator Contribution | Pfizer USA - small library of macrolides provided for screening. |
| Impact | Have identified new macrolides with Pfizer, still awaiting outcomes. The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved. |
| Start Year | 2010 |
| Description | Giamas - P47199 - Biofocus |
| Organisation | Biofocus |
| Country | United States |
| Sector | Private |
| PI Contribution | Giamas' team provided Biofocus with the protein to do the assay/screening. |
| Collaborator Contribution | Biofocus performed the screening and analysed the data. |
| Impact | None stated |
| Start Year | 2013 |
| Description | Giamas - P47199 - OPPF |
| Organisation | Research Complex at Harwell |
| Department | Oxford Protein Production Facility-UK (OPPF-UK) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | As part of this work and in collaboration with OPPF (Oxford Protein Production Facility) Dr Giamas' team have generated additional LMTK3 constructs encompassing the kinase domain that were expressed in various systems (E. Coli, insect cells, etc). |
| Collaborator Contribution | As part of this work and in collaboration with OPPF (Oxford Protein Production Facility) Dr Giamas' team have generated additional LMTK3 constructs encompassing the kinase domain that were expressed in various systems (E. Coli, insect cells, etc). OPPF produced the proteins for use in these experiments. |
| Impact | Dr Giamas' team managed to generate more pure and conformationally accurate LMTK3 protein that has been tested positive for kinase activity in in vitro kinase assays. |
| Start Year | 2013 |
| Description | Giamas - P47199 - ProfNC |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Generated more pure and conformationally accurate LMTK3 protein that has been tested positive for kinase activity in in vitro kinase assays |
| Collaborator Contribution | This LMTK3 protein is currently being used by our collaborator Professor Naomi Chayen (Imperial College) in crystallography assays |
| Impact | Yes this is a multi-disciplinary collaboration: Basic research (molecular, cell biology) along with structural biology. |
| Start Year | 2013 |
| Description | Griesenbach - ICiC1 - Prof Amit Nathwani |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise in pulmonary gene transfer and the generation of suitable vectors. |
| Collaborator Contribution | Expertise in the relevant disease area and access to patients should a clinical trial be initiated. |
| Impact | N/A |
| Start Year | 2016 |
| Description | Griesenbach - P47167 - ProfAN |
| Organisation | University College London |
| Department | UCL Cancer Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration with Prof A Nathwani to ensure smooth progression of Professor Grisenbach's gene transfer strategies into clinic, once efficacy in pre-clinical models has been determined |
| Collaborator Contribution | Collaboration with Prof A Nathwani to ensure smooth progression of Professor Grisenbach's gene transfer strategies into clinic, once efficacy in pre-clinical models has been determined |
| Impact | n/a |
| Start Year | 2013 |
| Description | Griesenbach - P47167 - UKCFGTC |
| Organisation | Baylor College of Medicine |
| Department | Centre for Cell and Gene Therapy |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | All work performed within the UK CF Gene Therapy Consortium is performed in a collaborative fashion across the three sites. The relative contributions of each site are project specific. For the project in question efficacy testing of viral vectors was performed by the Imperial team. |
| Collaborator Contribution | All work performed within the UK CF Gene Therapy Consortium is performed in a collaborative fashion across the three sites. The relative contributions of each site are project specific. For the project in question viral vectors were produced by the Oxford arm of the consortium. |
| Impact | The Consortium is now the world's largest gene therapy group focused on a single disease, with a combined staff of over 50. Professor Griesenback's team of clinical trial programme is well underway. Medicor awarded £200,000 to the whole of the GTC for the continuation of Consortium CF Gene Therapy work. The award was made on 20/12/13. |
| Start Year | 2006 |
| Description | Herrero - ICiC1 - Dexcom, Inc, San Diego, USA |
| Organisation | Dexcom |
| Country | United States |
| Sector | Private |
| PI Contribution | Development of the ABC4D app iOS and backend software (Matlab and webserver) to perform the clinical trial. |
| Collaborator Contribution | Financial support and providing some feedback regarding the usability of the app. |
| Impact | N/A |
| Start Year | 2015 |
| Description | Herrero-Viñas - P47176 - C |
| Organisation | Cellnovo |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Cellnovo (pump manufacturer) is interested in incorporating Dr Herrero-Vinas' software solution (ABC4D) in their products. Dr Herrero-Vinas' team are currently working on such integration. |
| Collaborator Contribution | Cellnovo (pump manufacturer) is interested in incorporating Dr Herrero-Vinas' software solution (ABC4D) in their products. Dr Herrero-Vinas' team are currently working on such integration. |
| Impact | Dr Herrero-Vinas' team are looking at incorporating ABC4D application into the Cellnovo handheld unit, which already communicates to their insulin pump. |
| Start Year | 2014 |
| Description | Herrero-Vinas - P47176 - D |
| Organisation | Dexcom |
| Country | United States |
| Sector | Private |
| PI Contribution | Dexcom has provided Dr Herrero-Vinas' team with two investigational devices. The team's main aim is to promote their product among the scientific community since bigger stakeholders such as Medtronic currently dominate the market. Therefore, by acknowledging them in the publications and conferences, the team are benefiting them by publicizing their product. |
| Collaborator Contribution | Dexcom has provided Dr Herrero-Vinas' team with two investigational devices. The team's main aim is to promote their product among the scientific community since bigger stakeholders such as Medtronic currently dominate the market. Therefore, by acknowledging them in the publications and conferences, the team are benefiting them by publicizing their product. |
| Impact | N/A |
| Start Year | 2014 |
| Description | ICiC 1 - Schneider - Novel inhibitors of Nemo-like kinase (NLK) to suppress cardiac muscle cell death |
| Organisation | Domainex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Target selection, forward plan for in-cell function and progression to small-mammal models |
| Collaborator Contribution | Fragment-based screen and medicinal chemistry |
| Impact | No outputs yet |
| Start Year | 2017 |
| Description | ICiC 1 - Sriskandan - GSK Golden Triangle Grand Challenge |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Proposed the collaboration and ideas; provided reagents and expertise; collaborated and monitored progress; Provided PhD student to undertake some scientific work |
| Collaborator Contribution | Commercial partner undertook large amount of scientific work |
| Impact | Work that will contribute to a PhD thesis. Work that will contribute to joint papers in due course. |
| Start Year | 2017 |
| Description | Long - P46365 - Uni of Manchester |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We made the compound that Professor Allen then tested in a stroke model, coupled with magnetic resonance imaging (MRI) |
| Collaborator Contribution | Prof Allen tested the compound in his in vivo stroke model and then performed MRI |
| Impact | This project has strengthening the link between Professor Allen and Professor Long's group, and further between Manchester University and Imperial College. |
| Description | Oliver ICiC - University of Surrey |
| Organisation | University of Surrey |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Develop and clinically assess a novel continuous glucose monitor (CGM) that overcomes challenges facing commercially available CGM technology by providing an accurate, painless minimally invasive device. |
| Collaborator Contribution | To obtain a higher quality of gold coating for the device (essential for its intended function), Nick Oliver's team used the conformal sputtering machine at University of Surrey. |
| Impact | Obtaining gold coated devices of higher quality |
| Start Year | 2013 |
| Description | Quinlan - DrND |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | At Imperial we have produced a functioning a filter prototype. |
| Collaborator Contribution | UCL will test this (filter prototype) in an in vivo model of haemolysis. |
| Impact | Multidisciplinary; within Imperial involving Medicine and Chemistry and from UCL hepatology. Functioning prototype produced |
| Start Year | 2013 |
| Description | Quinlan - ICiC1 - BPL |
| Organisation | Bio Products Laboratory Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | BPL are the providers of Haptoglobin which is utilised as a component of the filter device. Gregory Quinlan's team actually have a CDA in place with BPL going back seven years (facilitated though UCL). |
| Collaborator Contribution | Gregory Quinlan's team are about to send them a technical report including a description our expectations from BPL. This collaboration was initiated prior to the ICiC award but is important to Dr Quinlan's ICiC1 project. |
| Impact | A device in the form a filter to remove haemoglobin and related products from blood for the incorporation in extracorporeal circuits. |
| Start Year | 2007 |
| Description | Schneider - PS2145 - Domainex |
| Organisation | Domainex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Schneider laboratory has been responsible for the cell biology, functional genomics, and molecular physiology: namely, the development and implementation of cardioprotection assays in human pluripotent stem cell-derived cardiomyocytes, the RNA interference results validating MAP4K4 as a druggable target in the human context, and demonstrating the effectiveness of our best compound in this system. |
| Collaborator Contribution | We have collaborated with Cambridge drug discovery firm Domainex since mid-2013 for molecular modelling, medicinal chemistry, and strategic advice. In addition, the cell-free assays have been performed by Dr Chapman there. |
| Impact | This is a multi-disciplinary collaboration, including cell biology, functional genomics, and molecular physiology. |
| Start Year | 2013 |
| Description | Snelgrove - ICiC1 - DAG |
| Organisation | University of Alabama at Birmingham |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Provision and testing of our novel Leukotriene A4 hydrolase (LTA4H) modulators in murine models and clinical samples |
| Collaborator Contribution | Provision of specific mouse strains and expertise in murine models. Provision of clinical samples. Some downstream analysis. |
| Impact | No impact so far, collaboration and work still on-going. |
| Start Year | 2015 |
| Description | Snelgrove - ICiC1 - PIP & DMB |
| Organisation | University of Oxford |
| Department | Nuffield Department of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Measurement of Leukotriene B4 (LTB4) and PGP in clinical samples via mass spectrometry. |
| Collaborator Contribution | Provision of clinical samples. |
| Impact | Studies formed part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme. |
| Start Year | 2015 |
| Description | Snelgrove - ICiC1+2 - DrSH |
| Organisation | Imperial College London |
| Department | Department of Life Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Generation / provision of novel Leukotriene A4 hydrolase (LTA4H) modulators and recombinant LTA4H enzyme. Knowledge of LTA4H active site and Structure-Activity Relationship (SAR) studies. |
| Collaborator Contribution | Expertise in X-ray crystallography - conducted experiments and analysis. |
| Impact | Successful generation of X-ray crystallography structures of lead compounds bound within active site of LTA4H. These will form part of a manuscript currently in preparation. They were also part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme. |
| Start Year | 2014 |
| Description | Snelgrove - ICiC1+2 - ProfCL |
| Organisation | Imperial College London |
| Department | National Heart & Lung Institute (NHLI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have utilised Professor Lloyd's models of allergic airways disease to test our LTA4H knock-out mice and LTA4H modulators. We conducted all experiments and analysis with some technical help from Professor Lloyd's group, |
| Collaborator Contribution | Professor Lloyd is a world leader in murine models of allergic airways disease. She has provided expertise and knowledge of the models and her group have provided technical assistance. |
| Impact | Successful application for an Asthma UK Innovations award. Studies also formed part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme. These studies are the subject of a manuscript currently being finalized. |
| Start Year | 2013 |
| Description | Snelgrove - Peakdale Molecular |
| Organisation | Peakdale Molecular |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have formed a collaboration with Peakdale Molecular for the outsourcing of drug synthesis. Whilst there is an on-going narrative between ourselves and Peakdale about the drug synthesis pathways, they are largely providing a service. |
| Collaborator Contribution | In essence, we inform them of the compounds that we would like synthesized and then subsequently pay them to make them |
| Impact | The collaboration has been successful in the synthesis of novel compounds that show distinction between the dual activities of LTA4H, as well as the production of current pharmaceutical LTA4H inhibitors (to which we will be comparing our compounds ). |
| Start Year | 2013 |
| Description | Stronach - P47197 - Cyprotex |
| Organisation | Cyprotex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The interaction with Cyprotex was purely fee for service for kinome screen and ADMET assays respectively. |
| Collaborator Contribution | The interaction with Cyprotex was purely fee for service for kinome screen and ADMET assays respectively. |
| Impact | Nothing stated |
| Start Year | 2013 |
| Description | Stronach - P47197 - Dundee MRC |
| Organisation | Dundee Model Railway Club |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The interaction with Dundee MRC unit was purely fee for service for kinome screen and ADMET assays respectively |
| Collaborator Contribution | The interaction with Dundee MRC unit was purely fee for service for kinome screen and ADMET assays respectively |
| Impact | We have commissioned the Dundee MRC Unit to run kinase profiling on 4 compounds. This is underway and we await data return. This will give us key information on how clear or otherwise the compounds are. |
| Start Year | 2013 |
| Description | Stronach - P47197 - Edinburgh Bioquarter |
| Organisation | Edinburgh bioQuarter |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | None stated |
| Collaborator Contribution | The Edinburgh BioQuarter collaboration began with this project in 2013. BioQ provided important validation of compound phenotype effects in an independent lab. They also carried out detailed time course proteomics and identified pharmacodynamic biomarkers of compound activity. The data produced collectively is being compiled into a patent application for the key structures produced within this project. This is in progress. |
| Impact | n/a as this is still on-going |
| Start Year | 2013 |
| Description | Taylor-Robinson - ICiC 1 - Prolifica (IMF) |
| Organisation | Merieux Institute |
| Country | France |
| Sector | Private |
| PI Contribution | The Taylor-Robinson group have ongoing liver cancer biomarker work in Africa to develop a low cost urinary diagnostic which is being funded by Institut Merieux. The monies have facilitated collection of samples by the team in Nigeria, Gambia and Senegal and the analysis of samples at Imperial College London |
| Collaborator Contribution | Financial funding - Ongoing Institut Merieux funding until August 2016 (2 years) for 100,000 euros per year to further fund the liver cancer biomarker work in Africa |
| Impact | Not yet - ongoing |
| Start Year | 2014 |
| Description | Wigneshweraraj - P47143 - D |
| Organisation | Domainex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Prof. Wigneshweraraj's team screened the efficiency of libraries of small molecules identified by Domainex scientists to inhibit the enzymatic activity of the bacterial RNA polymerase and growth of Escherichia coli. |
| Collaborator Contribution | Prof. Wigneshweraraj's team screened the efficiency of libraries of small molecules identified by Domainex scientists to inhibit the enzymatic activity of the bacterial RNA polymerase and growth of Escherichia coli. |
| Impact | We are currently preparing a preliminary application for a Wellcome Trust SDDI scheme. Awaiting decision from a BBSRC grant application. |
| Start Year | 2013 |
| Title | Advance Bolus Calculator for Diabetes Management (ABC4D) |
| Description | The Advanced Bolus Calculator for Diabetes (ABC4D) is a decision support system based on case-based reasoning (CBR). CBR is an artificial intelligence problem solving framework that solves a newly encountered problem (e.g. meal insulin dosing), based on the information obtained from previously solved problems (cases). ABC4D is implemented in a smartphone application and utilises continuous glucose monitoring data to provide personalised and adaptive insulin bolus advice. Safety and clinical feasibility of the ABC4D app have been evaluated on 10 type 1 subject over a period of 6 weeks. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | N/A |
| Title | DIAGNOSTIC METHOD |
| Description | Methods and kits for analysing a sample from a test subject. The methods involve determining the level of at least one compound selected from the group consisting of N- acetylglutamate, methionine, acetylcarnitine, indole-3 -acetate, 2-oxoglutarate, anserine, aspartate and butyrate in the sample from the test subject; and comparing the level of the at least one compound determined to at least one control level, wherein the levels of the at least one compound are indicative of whether the subject has hepatic cancer. |
| IP Reference | WO2014174275 |
| Protection | Patent granted |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | None stated |
| Title | Methods for categorising cancer such as breast cancer |
| Description | LMTK3 as a prognostic marker for breast cancer treatment and to select appropriate therapy |
| IP Reference | US20110123386 |
| Protection | Patent application published |
| Year Protection Granted | 2010 |
| Licensed | No |
| Impact | Breast Cancer Campaign small Pilot grant nominated to Dr Georgios Giamas (Ref No: 2013MaySP004). 'Assay development and hit finding against LMTK3'. 1 year grant from 19th August 2013. Total value = £20,000. Action Against Cancer grant. PI: Prof Justin Stebbing. 'Assay Development and Compounds Screening for LMTK3'. 1st July 2012 to 30th June 2015. Total value = £78,000 9th International Conference of Anticancer Research, 6-10 October 2014, Sithonia, Greece (Oral presentation) 'Positioning LMTK3 on the map of oncogenic signalling cascades and elucidating its role in invasion and metastasis in Breast Cancer' |
| Title | Coombes - ICEC0942 |
| Description | We have developed selective small molecule inhibitors of cyclin-dependent kinases, CDK7 and CDK9, which are required for regulation of transcription in metazoans. Cancer features many oncogenes that are transcriptional regulators and targeting transcription would provide a powerful anti-tumour strategy. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Actively seeking support |
| Impact | N/A |
| Title | Giamas - LMTK3 inhibitor |
| Description | This work is currently funded by Action Against Cancer. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2014 |
| Development Status | Actively seeking support |
| Impact | N/A |
| Title | Herrero-Viñas - P47176 - ABC4D |
| Description | This study aims to assess the safety and efficacy of a novel advanced bolus calculator in subjects with Type 1 diabetes. Insulin bolus calculators have been developed to aid insulin dose adjustment and existing standard insulin bolus calculator consist of a simple algorithm that requires five subject-specific parameters as input to generate a recommended bolus insulin dose: current blood glucose (mmol/L); target blood glucose (mmol/L); insulin-to-carbohydrate ratio (grams of carbohydrate per 1 unit of insulin); total grams of carbohydrate in meals; insulin sensitivity factor (reduction in glucose per 1 unit of insulin). The Diabetes Technology team at Imperial College have developed a novel advanced bolus calculator. The complete integrated system consists of a commercially available smartphone that holds the novel advanced algorithm. The system requires regular updates of cases derived from retrospective blinded continuous glucose monitoring data and for this a commercially available glucose sensor will be used. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (blood glucose following a meal). The novel decision support algorithm is based on case-based reasoning (CBR). CBR is an artificial intelligence technique that tries to solve newly encountered problems by applying the solutions learned from solved problems encountered in the past. The end-product is therefore a subject specific insulin bolus calculator that continues to improve with time. The project utilises commercially available glucose sensors and smartphones (iPhone), integrated with a novel algorithm for insulin bolus calculation. The aim of the ABC4D is to minimise high and low glucose excursions which are associated with the complications of diabetes including blindness, kidney failure, nerve damage and cardiovascular disease. The clinical study has been designed to incrementally assess the device's ability to manage meal time insulin requirements at breakfast and lunch in a controlled supervised clinical environment over 8 hours (phase 1), followed by its use in the home environment over a 6 week period (phase 2) and finally over a 6 month period (phase 3). The most recent principle source of funding has been 'Imperial Confidence in Concept Scheme & Imperial NIHR Biomedical Research Centre /Imperial Innovations Therapeutic primer fund'. The clinical trial (phase 2) is currently active with the available funding. We are currently actively seeking for more funding to carry out the next phase of the clinical trial (phase 3). |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Very positive feedback on usability of the ABC4D system was obtained from a focus group carried out with six volunteers with type 1 diabetes. |
| URL | http://clinicaltrials.gov/show/NCT02053051 |
| Title | Oliver ICiC - Microprobe array continuous glucose monitor |
| Description | The device consists of a patch containing several microscopic projections. When applied to skin surface, these projections painlessly penetrate the outermost skin layer to sense glucose level within the tissues in a continuous manner. It aims at overcoming drawbacks of existing technology particularly by providing painless and more accurate continuous glucose readings. We are currently assessing the device's safety and performance in clinical studies and we are funded by a grant for NIHR I4I scheme. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | Potentially, the device could allow a more accurate and significantly cheaper technology for continuous glucose monitoring (CGM), which can subsequently result in wider use of this technology in people with diabetes. CGM was shown to improve control of diabetes with subsequent reduction in complications. |
| URL | http://clinicaltrials.gov/ct2/show/NCT01908530?term=microprobe&rank=1 |
| Title | Simonds ICiC - Evaluating intelligent oxygen therapy |
| Description | NIHR Respiratory BRU funding for PhD fellow |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Trial ongoing |
| Description | Edwards - P47173 - American Thoracic Society |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | poster presentation |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Presented a poster at at poster discussion session (ATS) the audience were approx several hundred, the abstract would reach several thousand. Novel inhibitors of TGF-beta activating kinase (TAK1) uncouple beneficial anti-viral innate immunity from harmful virus-induced pro-inflammatory responses in models of rhinovirus infection. Michael R. Edwards, Katie Chapman, Jennifer J. Haas, Louise Slater, Albert Jaxa-Chamiec, Caroline Low, Hayley Cordingley, Roberto Solari, Sebastian L. Johnston Catherine Tralau-Stewart. Poster Presentation, American Thoracic Society, San Diego, USA 2014. N/A |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.thoracic.org/ |
| Description | Edwards - XVI International Symposium on Respiratory Viral Infections Seoul, Korea 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | paper presentation |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Presented a seminar at a virology conference (RVI) the audience were approx several hundred, the abstract would reach several thousand. N/A |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.themacraefoundation.org/wp-content/uploads/2013/08/Final-Program-2.pdf |
| Description | Edwards, M - American Thoracic Society, San Francisco |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Azithromycin Augments RV-Induced Type I & III IFN Production Via Interaction with MAVS Michael R. Edwards, James D. Porter, Musa Khaitov, Sergei Moshkovski , Lyn Jones, Lee Roberts, Kalesh K.N. Anandamma, Iain Kilty, Ed Tate, Sebastian L. Johnston. Oral Presentation, American Thoracic Society, San Francisco, USA 2016. A talk of 15 minutes, and discussion for 5-7 mins including questions from the audience. Outcome was to disseminate information regarding science and asthma treatments. Outcome or impact is unknown. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.atsjournals.org/doi/abs/10.1164/ajrccmconference.2016.193.1_MeetingAbstracts.A6421 |
| Description | Gavins - Experimental Biology 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | paper presentation |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Research presentation to colleagues biology and imaging fields. Good discussion on specific and wider aspects of f-element chemistry N/A |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://experimentalbiology.org/2014/Home.aspx |
| Description | Giamas - P47199 - 9th International Conference of Anticancer Research 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Approximately 50 scientists attended the talk, followed by questions and discussion. Potential future collaborations with other groups were discussed. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.iiar-anticancer.org/conference/ |
| Description | Griesenbach - ICiC1 - Rare Disease Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Raising awareness for genetic diseases. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Griesenbach - Imperial Festival |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Approximately 12,000 people attended Imperial Festival over 3 days. Sharing information and improving public understanding of research |
| Year(s) Of Engagement Activity | 2012,2014 |
| URL | http://www3.imperial.ac.uk/festival |
| Description | Griesenbach - P47167 - Heart and Lung Repair Shop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | The audience were asked to vote on The Heart and Lung Repair Future Challenges. The winning challenge, receiving 699 votes, was 'Repair Your Own Organs' which was a challenge to develop drugs to stimulate the body's own stem cells to heal itself. The other challenges were 'Build a Heart' receiving 184 votes, 'Make Cigarettes Healthy' receiving 278 votes and 'Better Treatment for Lung Cancer' receiving 408 votes; special events were held including debates about the future of heart and lung repair, facilitated by Y Touring Theatre Company and a debate workshop with students from Hammersmith Academy. 2750 people visited The Heart and Lung Repair Shop during the two weeks it was open. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/heart_and_lung_repair_shops/ |
| Description | Griesenbach - P47167 - In2SUK |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | In2science scheme works to leverage the commitment, passion and experience of scientists to ensure the brightest pupils have the opportunity to experience research science first hand, regardless of their wealth. Students work alongside practising scientists for a 2 week placement during the summer, giving students an insight into scientific research. Placements will be highly valued by future employers and admissions tutors at centres of higher education and will enable scientists to inspire the next generation. Several students requested to visit the laboratory to gain relevant experience before applying to university |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://in2scienceuk.org/scientist.html |
| Description | Griesenbach - P47167 - Rare Disease Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Since Rare Disease Day was first launched by EURORDIS and its Council of National Alliances in 2008, more than 1000 events have taken place throughout the world reaching hundreds of thousands of people and resulting in a great deal of media coverage. Even though the campaign started as a European event, it has progressively become a world event, with a record-breaking 84 countries participating in 2014. IRRD hope many more will join in 2015. IRRD's objective is for the WHO to recognise the last day of February as the official Rare Disease Day and to raise increasing awareness for Rare Diseases worldwide. |
| Year(s) Of Engagement Activity | 2008,2010,2012,2013,2014 |
| URL | http://www.rarediseaseday.org/article/what-is-rare-disease-day |
| Description | Griesenbach - P47167 - STEML |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | The event aims to provide an insight on current popular research areas in different subject fields, and also gives students a chance to explore university life from a different prospective. Several students requested to visit the laboratory to gain relevant experience before applying to university |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/administration/outreach/eventssummary/... |
| Description | Herrero - ICiC 1 - IBC |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of the ABC4D system at the symposium organised by Astra-Zeneca entitled "Advances in Diabetes Technologies, Management and Prevention - An insight into Imperial College London's Innovative Research" |
| Year(s) Of Engagement Activity | 2017 |
| Description | Herrero - ICiC 1 - IBC 2 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of the ABC4D system at the symposium organised by Centre for Continuing Professional Development, Imperial College |
| Year(s) Of Engagement Activity | 2017 |
| Description | Herrero - ICiC1 - Astra-Zeneka sponsored event in Madrid |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | More than 100 endocrinologists and around 15 from around Spain from Astra-Zeneka attended the talk (1 hour) about the ABC4D system which sparked questions and discussion afterwards. |
| Year(s) Of Engagement Activity | 2017 |
| Description | ICiC 1 - Herrero - Advanced Technologies & Treatments for Diabetes (ATTD) conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 500 people attended the talk, which sparked questions and discussion afterwards |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://attd.kenes.com/2019#.XI_U-pP7Si4 |
| Description | ICiC 1 - Herrero - Scientific Sessions of the American Diabetes Association (ADA) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 1000 people attended the talk, which sparked questions and discussion afterwards |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://professional.diabetes.org/meeting/scientific-sessions/78th-scientific-sessions |
| Description | ICiC 1 - Herrero - World Precision Medicine, AI in healthcare conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 50 people attended the talk, which sparked questions and discussion afterwards |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://allseq.com/conferences/world-precision-medicine-2018/ |
| Description | ICiC 1 - Sriskandan - 2. Invited lecture and participation in a WHO Consultation on Group A Streptococcal Vaccines May 16-17, 2018, held at the Wellcome Trust. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | Roughly 50 attendees from around the world attended seminars and a workshop held at the Wellcome Trust organised by WHO about prospects for a global effort to develop a vaccine for group A streptococcus, and to develop a roadmap towards this goal, with funders, policymakers, and academics. This had led on to an application from IVI for a GAS Vaccine Consortium to Wellcome, and a federal award of A$35m from the Australian government to academic partners in Australia to further support development of a GAS vaccine. |
| Year(s) Of Engagement Activity | 2018 |
| Description | ICiC 1 - Sriskandan - Imperial Vaccines Network symposium about commercial barriers to developing the most effective bacterial vaccines April 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Third sector organisations |
| Results and Impact | seminars given here were to other academics and stakeholders in the field including commercial vaccine developer. This led on to an active collaboration with the vaccine developer and a joint BBSRC iCASE (NPIF) studentship |
| Year(s) Of Engagement Activity | 2018 |
| Description | ICiC 1 - Sriskandan - Invited seminar at the Institute of Global Health Innovation April 19th 2018 about " Why do we not have a vaccine for group A streptococcus?" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Third sector organisations |
| Results and Impact | Seminars given here were to other academics and stakeholders in the field including commercial vaccine developer. This led on to an active collaboration with the vaccine developer and a joint BBSRC iCASE (NPIF) studentship |
| Year(s) Of Engagement Activity | 2018 |
| Description | JDRF Discovery Evening |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Members of the ICiC project on Advanced Bolus Calculator for Diabetes presented their work at this event. This was an opportunity for adults living with type 1 diabetes to meet others with the condition and learn about the latest Juvenile Diabetes Research Foundation research. The event also included inspirational talks from adults living and working with Type 1 diabetes Event occurred on 13th November 2013, no impact so far |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.jdrf.org.uk/research/research-events/type-1-discovery-evening |
| Description | Long - P46365 - Dalton Discussion meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | paper presentation |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | There were presentations of research work, followed by extended question and answer sessions, where research issues were aired and talked through. This will affect future research and help to guide others research. There were further discussions during the lunch and evening sessions and the papers will be collected within a special issue of Dalton Transactions in February 2015. As above, a special issue of the main UK inorganic chemistry journal will be the results of the meeting. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.rsc.org/ConferencesAndEvents/RSCConferences/DD15/ |
| Description | Long - P46365 - DrGS - EU COST (EUFEN3) action meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | paper presentation |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Research presentation to colleagues in the f-element field. Good discussion on specific and wider aspects of f-element chemistry Good discussion on specific and wider aspects of f-element chemistry |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.nottingham.ac.uk/~pczstl/CM1006/EUFEN3.htm |
| Description | Long/Gavins - P46365 - Pharmacology 2014, London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | poster presentation |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Poster presentation given at pharmacology 2014 conference London. We hope the presentation will reach a wide audience and initiate conversations and debate about the work and future directions. n/a |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.bps.ac.uk/meetings/Pharmacology2014 |
| Description | Oliver ICiC - The microprobe sensor advisory group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Local |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | The group is formed of 8 members and meets on regular interval to discuss update and plans for the following phase of the project. It allowed the group to view the project from patients' perspective and to modify the protocol accordingly. As mentioned, the group participated in protocol and in developing participant information material. The PPI at an early stage of this project was positively viewed by reviewers of the NIHR i4i grant (awarded on June 2013). |
| Year(s) Of Engagement Activity | 2012,2013,2014 |
| Description | Shamji - British Society of Allergy and Immunology meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | British Society of Allergy and Immunology (BSACI) meeting, Telford, UK Research findings were presented at the BSACI meeting. The symposium was attended by 50-100 delegates. Questions and Answer session was followed after the presentation N/A |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.bsaci.org/announcements/bsaci-annual-meeting-2014 |
| Description | Shamji ICiC -American Academy of Allergy, Asthma and Immunology annual meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | poster presentation |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Diego, USA. The AAAAI featured poster session was well attended and a 5-10 minute presentations was given on the research, which was then followed by question and answer session. The session was attended by 50-100 delegates. N/A |
| Year(s) Of Engagement Activity | 2013,2014 |
| URL | http://annualmeeting.aaaai.org/ |
| Description | Simonds ICiC - European Respiratory Society (ERS) Summer School |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 80 doctors attended but presentations were disseminated on ERS website Small group discussions on 02 therapy |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.ersnet.org/ |
| Description | Stevens - ICiC1 - APS Pharm Sci |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Academy of Pharmaceutical Sciences held their annual PharmSci Conference at the University of Hertfordshire de Havilland campus, from 8th -10th September 2014. PharmSci 2014 addressed 'Working together for patients'. The conference attracted nearly 600 participants from academia, industry and regulatory authorities over the 3 days. The conference also provided many networking opportunities and an enjoyable social side with a lively debate on the Monday evening, 'The role of universities in open innovation research: academic entrepreneurship or industrial exploitation?' and on the Tuesday evening the APS annual "Black Tie" Dinner at Knebworth House with an inspirational talk from Elin Haf Davies |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.ukpharmsci.org/2014resourcepack/ |
| Description | Stevens - ICiC1 - Corday Morgan Lecture (Award) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Corday-Morgan Prizes are awarded for the most meritorious contributions to chemistry. It runs annually, there are up to three prizes available, winners receive £5000, a medal and a certificate, to be presented at the Prize ceremony in November, the winners will undertake UK lecture tours and prize winners are chosen by the RSC Awards Working Group. Prof Molly Stevens was the winner of this prize in 2014 |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.rsc.org/events/detail/17280/2014-corday-morgan-prize-winner-lecture |
| Description | Stevens - ICiC1 - Dara O'Brien's Science Club |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Invited as a guest expert |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.bbc.co.uk/programmes/b037mkj3 |
| Description | Stevens - ICiC1 - Fourth International Conference on Multifunctional, Hybrid and Nanomaterials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The main objective of this large interdisciplinary conference is to bring together, at a truly international level, people with shared interests in hybrid materials. Prof Stevens was a featured speaker. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.materialstoday.com/polymers-soft-materials/events/hybrid-materials-2015-/ |
| Description | Stevens - ICiC1 - HG |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | HG delivered the following oral presentation: Quantum dot-based detection of a tuberculosis-specific transcript signature, Materials Research Society Spring Meeting, San Francisco (April 2015) |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://epub.knepperpress.com/publication/index.php?i=249474&m=0&l=&p=318&pre=&ver=html5 |
| Description | Stevens - ICiC1 - Kavli Nanoscience Symposium, Tondheim |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Kavli Prizes are awarded biannually in Oslo within the fields of Nanoscience, Neuroscience and Astrophysics. |
| Year(s) Of Engagement Activity | 2014 |
| URL | https://www.ntnu.edu/physics/kavlis14 |
| Description | Stevens - ICiC1 - NPL Workshop: Nanoparticle concentration, chemistry and interfaces |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Workshop: Nanoparticle concentration, chemistry and interfaces. This four-day workshop will engage international experts in a lively scientific debate around the measurement of concentration of nanoparticle in media, their chemistry and the nature of critical interfaces. It was attended by member(s) of Prof Stevens group. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.npl.co.uk/np-workshop/ |
| Description | Stevens - ICiC1 - Nanotechnology & Medicines for Tomorrow |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Biomedical Research Victoria (BioMedVic) is the peak body for the organisations that make up this internationally-recognised research community, providing a collective voice for advocacy and a structure for promoting collaboration and innovation. Representing universities, teaching hospitals, medical research institutes, CSIRO and other research organisations, Biomedical Research Victoria seeks to develop shared vision, long term plans and better links between government, industry and the biomedical community. Prof Stevens was the plenary speaker at the November 2014 meeting |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://biomedvic.org.au/symposium/nanotechnology-and-medicines-for-tomorrow/ |
| Description | Stevens - PS2142_MMRE - MRSUS |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Over 6000 attended the 2014 MRS Spring Meeting, thus making it hugely successful. The presentations and discussions of materials science and their impact in healthcare applications were very exciting and spurred numerous collaborations and new projects. Prof Stevens was interviewed by MRS TV to discuss the exciting scientific talks and atmosphere present at the meeting, where several Stevens Group members also presented their work. The MRS Meetings are an excellent source for materials-based research scientists to present their latest results and network with peers to strengthen their research directions and possibilities. This Spring Meeting was an incredible display of the level of research currently ongoing in our fields |
| Year(s) Of Engagement Activity | 2014,2015 |
| URL | http://www.mrs.org/spring2014/ |
| Description | Taylor-Robinson - ICiC1 - AMMF |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | AMMF held a research update event at Imperial College in Feb 2015. 200 members of the public attended an open day at Imperial College London with a series of lectures on our research and the opportunities to ask questions in a "Question Time" debate |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.ammf.org.uk/2015/03/16/ammf-at-imperial-college-11-03-15/ |
| Description | Wigneshweraraj - ICiC1 - RNA Polymerase Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The Annual RNA Polymerase Workshop, hosted by David Grainger and David Lee, came to the University of Birmingham last week. The workshop ran over two days and featured 22 talks across four sessions. The overall focus of the meeting was the mechanism and regulation of transcription. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://imibirmingham.com/2015/05/13/an-overview-of-the-27th-uk-rna-polymerase-workshop-2/ |